Sponsors (4)
The resolution promotes earlier detection, monitoring, and treatment access for tardive dyskinesia among people on antipsychotics/antiemetics—improving patient outcomes—while risking higher healthcare costs and possible increased anxiety or stigma for those patients.
Adults taking antipsychotic or antiemetic medications will be more likely to be screened and diagnosed earlier for tardive dyskinesia, improving timely access to FDA‑approved TD treatments and reducing progression of disabling symptoms.
Clinicians and the public will have increased awareness and routine monitoring for TD, which should raise detection rates and improve linkage to care and ongoing management for affected individuals.
Expanded screening, monitoring, and greater uptake of TD therapies may increase healthcare costs for patients, insurers, and taxpayers.
Heightened public and medical messaging about TD could increase anxiety or stigma among people taking antipsychotics or antiemetics, potentially deterring some from needed treatment.
Based on analysis of 1 section of legislative text.
Finds that tardive dyskinesia is an underdiagnosed condition linked to certain medications and calls for increased awareness, regular monitoring, and treatment for adults with TD.
Official title: Expressing support for the designation of the week of May 3, 2026, through May 9, 2026, as "Tardive Dyskinesia Awareness Week".
Introduced May 7, 2026 by Scott Peters · Last progress May 7, 2026
Declares findings that tardive dyskinesia (TD) is a potentially serious involuntary movement disorder that can result from prolonged use of dopamine receptor blocking agents, including antipsychotics and some antiemetics. Notes an estimated 600,000 people in the U.S. may have TD (about 60% undiagnosed), emphasizes the physical, social, and emotional harms even from mild symptoms, highlights clinical guidance recommending regular monitoring, and observes that FDA‑approved treatments exist for adults with TD. Encourages increased awareness and screening by health care providers and the public so more people with TD are recognized and can receive appropriate care and treatment.